Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | NPPA | P01160 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807187 | 0.94 | PPARA (0.48) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL30306923 | 0.94 | ATM (0.43) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL6806843 | 0.94 | MGLL (0.43) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL6254719 | 0.89 | NPPA (0.52) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL6807219 | 0.88 | SYK (0.47) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL6259306 | 0.86 | PPARA (0.47) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL28969031 | 0.84 | NPPA (0.47) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL28968928 | 0.84 | NPPA (0.47) | ATMTACR1NPPAMMECTSL | |
| SCHEMBL6803500 | 0.82 | TACR1 (0.61) | ATMTACR1CTSLCTSBCTSS | |
| SCHEMBL6257672 | 0.82 | ATM (0.46) | ATMTACR1NPPAMMECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005123702-A1 | NEUTRAL ENDOPEPTIDASE INHIBITOR POLYMORPH | PFIZER LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123702-A1 | NEUTRAL ENDOPEPTIDASE INHIBITOR POLYMORPH | PFIZER LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | ATM 4873/4885TACR1 489/4885NPPA 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.